Dehydroepiandrosterone for women in the peri- or postmenopausal phase

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2015, Pages

  Scheffers, Carola S ^a   Armstrong, Sarah ^b   Cantineau, Astrid E P ^a,c   Farquhar, Cindy ^b   Jordan, Vanessa ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; CLONIDINE; CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; ESTROGEN; PLACEBO; PRASTERONE; PROGESTERONE; TIBOLONE; VITAMIN D;

ACNE; ACUPUNCTURE; ALTERNATIVE MEDICINE; ANDROGEN THERAPY; CLIMACTERIUM; CONTACT DERMATITIS; DEPRESSION; DIZZINESS; DREAM; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; HIRSUTISM; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; MUSCLE CRAMP; PARESTHESIA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; WELLBEING; ACNE VULGARIS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; DYSPAREUNIA; FEMALE; HOT FLASHES; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELECTION BIAS; SWEATING;

ACNE VULGARIS; DEHYDROEPIANDROSTERONE; DYSPAREUNIA; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; PERIMENOPAUSE; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTION BIAS; SWEATING;

EID: 85019516967     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011066.pub2     Document Type: Review

References (110)

1. Amin MB, Buster JE, Callas P, Burger N, Pisarska M, Casson PR. The cognitive/psychological effect of dose titrated DHEA supplementation in post-menopausal women. Fertility and Sterility 2005; Vol. 84, issue Supp 1:S119.
2. Barnhart KT, Freeman E, Grisso JA, Neslter J. The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility 1998; Vol. 70, issue 3:S25.
3. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. Journal of Clinical Endocrinology and Metabolism 1999; Vol. 84 (11):3896-902.
4. Rader D, Freeman E, Kapoor SK, Smith P, Nestler J. The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility 1997:S41.
5. Bloch M, Aharonov I, Meiboom H, Ben-Avi I, Abramov L. The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine 2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527.
6. Bloch M, Meiboom H, Zaig I, Schreiber S, Abramov L. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology 2013; Vol. 23, issue 8:910-8.
7. Casson PR, Santoro N, Elkind Hirsch K, Carson SA, Hornsby PJ, Abraham G, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertility and Sterility 1998; Vol. 70, issue 1:107-10.
8. Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health 2005; Vol. 14, issue 5:391-400.
9. El-Alfy M, Deloche C, Azzi L, Bernard BA, Bernerd F, Coutet J, et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology 2010; Vol. 163, issue 5:968-76.
10. Finckh A, Berner IC, Aubry-Rozier B, So AK. 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society 2004; Vol. 52, issue 4:S1-S246.
11. Finckh A, Berner IC, Aubry-Rozier B, So AK-L. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology 2005; Vol. 32, issue 7:1336-40.
12. Forsblad-d'Elia H, Carlsten H, Labrie F, Konttinen YT, Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism 2009; Vol. 94, issue 6:2044-51.
13. Genazzani AR, Stomati M, Valentino V, Pluchino N, Pot E, Casarosa E, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011; Vol. 14, issue 6:661-8.
14. Valentino V, Nanini C, Donati E, Giannini A, Merlini S, Casarosa E, et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies 2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125.
15. Gomez-Santos C, Hernandez-Morante JJ, Tebar FJ, Granero E, Garaulet M. Differential effect of oral dehydroepiandrosterone-sulphate on metabolic syndrome features in pre- and postmenopausal obese women. Clinical Endocrinology 2011; Vol. 77, issue 4:548-54.
16. Gomez-Santos C, Larque E, Granero E, Hernandez-Morante JJ, Garaulet M. Dehydroepiandrosterone-sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids 2011; Vol. 76, issue 13:1425-32.
17. Gupta B, Mittal P, Khuteta R, Bhargava A. A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India 2013; Vol. 63, issue 3:194-8.
18. Hirshman E, Wells E, Wierman ME, Anderson B, Butler A, Senholzi M, et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin & Review 2003; Vol. 10, issue 1:125-34.
19. Hirshman E, Merritt P, Wang CC, Wierman M, Budescu DV, Kohrt W, et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior 2004; Vol. 45, issue 2:144-55.
20. Kratz KE. The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering 2000; Vol. 61, issue 5-B:2812.
21. Parsons T, Kratz K, Thompson E, Stanczyk F, Buckwalter J. DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience 2006; Vol. 116, issue 2:141-55.
22. Kritz-Silverstein D, von Muhlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. Journal of the American Geriatrics Society 2008; Vol. 56, issue 7:1292-8.
23. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1997; Vol. 82 (10):3498-505.
24. Labrie F, Cusan L, Gomez JL, Cote I, Berube R, Belanger P, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology 2008; Vol. 111, issue 3-5:178-94.
25. Labrie F, Martel C, Berube R, Cote I, Labrie C, Cusan L, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology 2013; Vol. 138:359-67.
26. Bouchard C, Archer D, Labrie F, Fortier M, Cusan L, Gomez JL, et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas 2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39.
27. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J-L, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009; Vol. 16, issue 5:923-31.
28. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J-L, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009; Vol. 16, issue 5:907-22.
29. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J-L, et al. Lack of inuence of dyspareunia on the bene'cial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine 2014;11(7):1766-85. [DOI: 10.1111/jsm.12517]
30. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J-L, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009; Vol. 16, issue 5:897-906.
31. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause 2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232-3.
32. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology 2010; Vol. 26, issue 7:524-32.
33. Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011; Vol. 14, issue 2:282-8.
34. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology 2001; Vol. 145, issue 4:457-61.
35. Merritt P, Stangl B, Hirshman E, Verbalis J. Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women. Brain Research 2012; Vol. 1483:54-62.
36. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1990; Vol. 71 (3):696-704.
37. Nouveau S, Bastien P, Baldo F, de Lacharriere O. Effects of topical DHEA on aging skin: a pilot study. Maturitas 2008; Vol. 59, issue 2:174-81.
38. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 2009; Vol. 63, issue 3:240-5.
39. Panjari M, Bell RJ, Jane F, Wolfe R, Adams J, Morrow C, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine 2009; Vol. 6, issue 9:2579-90.
40. Pluchino N, Ninni F, Stomati M, Freschi L, Casarosa E, Valentino V, et al. One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas 2008; Vol. 59, issue 4:293-303.
41. Silvestri A, Gambacciani M, Vitale C, Monteleone P, Ciaponi M, Fini M, et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas 2005; Vol. 50, issue 4:305-11.
42. Stanczyk FZ, Slater CC, Ramos DE, Azen C, Cherala G, Hakala C, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause 2009; Vol. 16, issue 2:272-8.
43. Stangl B, Hirshman E, Verbalis J. Administration of dehydroepiandrosterone (DHEA) enhances visual-spatial performance in postmenopausal women. Behavioral Neuroscience 2011; Vol. 125, issue 5:742-52.
44. Stangl BL. The mediation of cognitive task performance in post-menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering 2010; Vol. 71, issue 4-B:2714.
45. Stomati M, Rubino S, Spinetti A, Parrini D, Luisi S, Casarosa E, et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology 1999; Vol. 13, issue 1:15-25.
46. Barton DL, Loprinzi C, Atherton PJ, Kottschade L, Collins M, Carpenter P, et al. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Supportive Cancer Therapy 2006; Vol. 3, issue 2:91-7.
47. Bates Jr GW, Egerman RS, Umstot ES, Buster JE, Casson PR. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Annals of the New York Academy of Sciences 1995; Vol. 774:291-3.
48. Burger N, Protas E, Davis B, Buster J, Carson S, Casson P. Effect of physiologic oral dehydroepiandrosterone (DHEA) replacement on exercise tolerance in postmenopausal women. Fertility and Sterility 2003; Vol. 80, issue Suppl 3:S241, Abstract no: P-362.
49. Buster JE, Casson PR, Straughn AB, Dale D, Umstot ES, Chiamori N, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. American Journal of Obstetrics and Gynecology 1992; Vol. 166, issue 4:1163-8; discussion 1168-70.
50. Buster JE. Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone Precursor Replacement Therapy (HPRT). Menopause 2009; Vol. 16 (5):858-9.
51. Calvo E, Luu-The V, Morissette J, Martel C, Labrie C, Bernard B, et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology 2008; Vol. 112, issue 4-5:186-93.
52. Carranza-Lira S, Najera Mojica JL, Herrera J, Ramos Ponce D, Olvares Segura A, Cardoso Saldana G, et al. Changes in hormones, lipids and symptoms after the administration of a commercial preparation with dehydroepiandrosterone in postmenopausal women. Proceedings of the Western Pharmacology Society 2002; Vol. 45:181-3.
53. Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. American Journal of Obstetrics and Gynecology 1993; Vol. 169, issue 6:1536-9.
54. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abraham GE, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertility and Sterility 1995; Vol. 63, issue 5:1027-31.
55. Caufriez A, Leproult R, L'Hermite-Baleriaux M, Kerkhofs M, Copinschi G. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study. Clinical Endocrinology 2013; Vol. 79, issue 5:716-24.
56. Chassany O. Does dehydroepiandrosterone improve well-being. [French]. Presse Medicale 2000; Vol. 29 (24):1354-5.
57. Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of Women's Health & Gender-Based Medicine 2002; Vol. 11, issue 2:155-62.
58. Hartkamp A, Geenen R, Godaert GLR, Bijl M, Bijlsma JWJ, Derksen RHWM. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis and Rheumatism 2004; Vol. 50, issue 11:3591-5.
59. Kamath SK, Murillo G, Chatterton RT, Jr, Hussain EA, Amin D, et al. Benefits of DHEA in postmenopausal women. Life Extension 1998; Vol. 4, issue 3:7.
60. Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 2013; Vol. 16, issue 2:205-13.
61. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, et al. Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. Journal of Clinical Endocrinology and Metabolism 2003; Vol. 88 (3):1112-8.
62. Ott J, Pecnik P, Promberger R, Pils S, Seemann R, Hermann M, et al. Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto's thyroiditis. Climacteric 2014; Vol. 17, issue 1:92-6.
63. Pisarska MD, Di Maio DJ, Carson SA, Buster JE, Casson PR. Oral dehydroepiandrosterone (DHEA) replacement therapy does not induce an estrogenic maturation of vaginal epithelium. Fertility and Sterility 1998; Vol. 70, issue 3:S124.
64. Rodrigo Pegado F, Araújo Moura M, Constantino, Bernarte Coriro M. Influence of cortisol and DHEA-S on pain and other symptoms in post menopausal women with fibromyalgia. Journal of Back & Musculoskeletal Rehabilitation 2012; Vol. 25, issue 4:245-52.
65. Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YRS, et al. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. Journal of Rheumatology 2008; Vol. 35, issue 8:1567-75.
66. Stein D, Bruemmer NC, Blum JM. Dietary supplement containing prohormones and all-natural nutrients that improves female sexual well-being. Journal of Sexual Medicine 2011; Vol. Conference: 10th Annual Meeting of the International Society for the Study of Women's Sexual Health, ISSM 2011 Sottsdale, AZ United States. Conference Start: 20110210 Conference End: 20110213. Conference Publication: (var.pagings). 8:77.
67. Stoll BA. Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk. European Journal of Clinical Nutrition 1999; Vol. 53, issue 10:771-5.
68. Virkki LM, Porola P, Forsblad-D'Elia H, Valtysdottir S, Solovieva SA, Konttinen YT. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjogren's syndrome. Arthritis Care and Research 2010; Vol. 62 (1):118-24.
69. Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. Androgen in postmenopausal women. Journal of Medical Investigation 2012; Vol. 59 (1-2):12-27.
70. Zouboulis CC, Makrantonaki E. Hormonal therapy of intrinsic aging. Rejuvenation Research 2012; Vol. 15, issue 3:302-12.
71. Igwebuike A, Irving BA, Bigelow ML, Short KR, McConnell JP, Nair KS. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2008; Vol. 93, issue 2:534-8.
72. Labrie F, Belanger A, Belanger P, Berube R, Martel C, Cusan L, et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. Journal of Steroid Biochemistry and Molecular Biology 2007; Vol. 103, issue 2:178-88.
73. Labrie F, Belanger A, Labrie C, Candas B, Cusan L, Gomez JL. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology 2007; Vol. 107, issue 1-2:57-69.
74. Labrie F, Cusan L, Gomez J-L, Martel C, Berube R, Belanger P, et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. Journal of Steroid Biochemistry and Molecular Biology 2008; Vol. 110, issue 1-2:1-9.
75. Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women. Ongoing study August 2005.
76. Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause. Ongoing study February 2014.
77. Buster J, Casson P. DHEA: Biology and Use in Therapeutic Intervention. Menopause: Biology and Pathobiology. Elsevier, 2000:625-38.
78. Buvat J. Androgen therapy with dehydroepiandrosterone. World Journal of Urology 2003;21:346-55.
79. Cameron D, Braunstein G. The use of dehydroepiandrosterone therapy in clinical practice. Treatments in Endocrinology April 2005;4(2):95-114.
80. Casson P, Straughn A, Umstot E, Abraham G, Carson S, Buster J. Delivery of dehydroepiandrosterone to premenopausal women: Effects of micronization and nonoral administration. American Journal of Obstetrics and Gynecology 1996;174(2):649-53.
81. Davis S, Moreau M, Kroll M, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England Journal of Medicine 2008;359:2005-17.
82. Dobs A, Nguyen T, Pace C, Roberts C. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2002;87:1509-16.
83. Genazzani A, Petraglia F, Artini P. Advances in Gynecological Endocrinology. London: The Parthenon Publishing Group, 2002.
84. Goel R, Cappola A. Dehydroepiandrosterone sulfate and postmenopausal women. Current Opinion in Endocrinology, Diabetes, and Obesity 2011;18(3):171-6.
85. Grimley Evans J, Malouf R, Huppert FAH, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation forcognitive function in healthy elderly people. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI:10.1002/14651858.CD006221 ]
86. Harlow S, Gass M, Hall J, Lobo R, Maki P, Rebar R, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism 2012;97(4):1159-68.
87. Heinemann K, Ruebig A, Potthoff P, Schneider H, Strelow F, Heinemann L, Minh Thai D. The Menopause Rating Scale (MRS): A methodological review. Health and Quality of Life Outcomes 2004;2(1):45.
88. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003;327:557.
89. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
90. Hoffman B, Schorge J, Schaffer J, Halvorson L, Bradshaw K, Cunningham F, Calver L. Chapter 21. Menopausal Transition. Williams Gynecology. 2nd Edition. McGraw-Hill, 2012.
91. Kroboth P, Salek F, Pittenger A, Fabian T, Frye R. DHEA and DHEA-S: a review. Journal of Clinical Pharmacology 1999;39:327-48.
92. Manson JA, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative Randomized Trials. JAMA 2013;310(13):1353-68.
93. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI:10.1002/14651858.CD004143.pub4 ]
94. Mayo M, Mayo J. The menopause manager. 3rd Edition. Fleming H. Revell, 2002.
95. Miller W. Androgen biosynthesis from cholesterol to DHEA. Molecular and Cellular Endocrinology 2002;198:7-14.
96. Morris K, Toth-Fejel S, Schmidt J, Fletcher W, Pommier R. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy. Surgery 2001;130(6):947-53.
97. Panjari M, Davis S. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010 June;66(2):172-9.
98. Pluchino N, Carmignani A, Cubeddu A, Santoro A, Cela V, Errasti Alcalà T. Androgen therapy in women: for whom and when. Archives of Gynecology and Obstetrics 2013;288:731-7.
99. Raven P, Hinson J. Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause International 2007;13(2):75-8.
100. Rosen M, Cedars M. Chapter 13. Female Reproductive Endocrinology and Infertility. In: Gardner D, Shoback D editor(s). Greenspan's Basic & Clinical Endocrinology. 9th Edition. New York: McGraw-Hill, 2011.
101. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33.
102. Sawahla AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Current Rheumatology Reports August 2008;10(4):286-91.
103. Schwartz A, Pashko L. Mechanism of cancer preventive action of DHEA. Annals of the New York Academy of Sciences 2006;774(1):180-6.
104. Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Research 2005;7(6):1132-40.
105. Simpson E. Sources of estrogen and their importance. Journal of Steroid Biochemistry and Molecular Biology 2003;86(3-5):225-30.
106. Sparke R, F.A.C.E. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertility and Sterility 2002;77(4):S19-S25.
107. Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams & Wilkens, 2005.
108. State-of-the-Science-Panel. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consensus and State-of-the-Science Statements 2005;22(1):1-38.
109. Taylor H, Manson J. Update in hormone therapy use in menopause. Journal of Clinical Endocrinology and Metabolism 2011;96:255-64.
110. Vanson A, Arnold A, Schlinger B. 3β-hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. General and Comparative Endocrinology 1996;102(3):342-50.